Yunfeng Liu, [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology ORCID: Yi Zhang, orcid.org/0000-0003-0305-3127 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Maybe you're part of the 15% for whom these drugs don't work
While some people respond to taking a very small dose called super responders others cannot tolerate moving up to the next higher standard dose and need something in between. This helps explain why one recent study among patients with diabetes found that microdosing helped them stick with their GLP-1s, reducing side effects without compromising efficacy
However, not all patients respond effectively to GLP-1R monoagonists, and higher doses aimed at increasing efficacy result in adverse gastrointestinal effects
This precision matters because contaminated or improperly formulated medications can increase gastrointestinal side effects
Stanford worries about equity issues
